Cognetivity Neurosciences Ltd
(OP:
CGNSF
)
0.0028
UNCHANGED
Streaming Delayed Price
Updated: 9:33 AM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
100
Open
0.0028
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0028
Today's Range
0.0028 - 0.0028
52wk Range
0.0011 - 0.1179
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AI-Powered Psychedelic Treatments: Special Status And Next-Gen Contests Winners
June 08, 2023
As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.
Via
Benzinga
UK-Based Psychedelics Ancillary Business Wraps Up $3M Funding Round
October 28, 2022
A tech company responsible for creating a clinical testing platform that uses AI and machine learning for the detection of earliest cognitive impairment signs, Cognetivity Neurosciences Ltd.
Via
Benzinga
Performance
YTD
-79.41%
-79.41%
1 Month
-3.45%
-3.45%
3 Month
-72.00%
-72.00%
6 Month
-84.27%
-84.27%
1 Year
-97.20%
-97.20%
More News
Read More
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
February 08, 2022
Via
Benzinga
Ketamine One Teams Up With Cognetivity Neurosciences To Study PTSD, Depression
December 02, 2021
Via
Benzinga
Cognitive Assessment And Training Market Size Expected To Reach $15.65 Billion In 2028
May 04, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Cognetivity Neurosciences and InterSystems Partner to Fast-track Integration of Early Dementia Detection with Global Healthcare Systems
May 04, 2021
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.